96 related articles for article (PubMed ID: 31628675)
21. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.
Sia D; Losic B; Moeini A; Cabellos L; Hao K; Revill K; Bonal D; Miltiadous O; Zhang Z; Hoshida Y; Cornella H; Castillo-Martin M; Pinyol R; Kasai Y; Roayaie S; Thung SN; Fuster J; Schwartz ME; Waxman S; Cordon-Cardo C; Schadt E; Mazzaferro V; Llovet JM
Nat Commun; 2015 Jan; 6():6087. PubMed ID: 25608663
[TBL] [Abstract][Full Text] [Related]
22. A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix.
Hara K; Saito T; Hayashi T; Yimit A; Takahashi M; Mitani K; Takahashi M; Yao T
Pathol Res Pract; 2015 Sep; 211(9):657-64. PubMed ID: 26160192
[TBL] [Abstract][Full Text] [Related]
23. Targeted next-generation sequencing of commonly mutated genes in esophageal adenocarcinoma patients with long-term survival.
Visser E; Franken IA; Brosens LAA; de Leng WWJ; Strengman E; Offerhaus JA; Ruurda JP; van Hillegersberg R
Dis Esophagus; 2017 Sep; 30(9):1-8. PubMed ID: 28859360
[TBL] [Abstract][Full Text] [Related]
24. Somatic Mutations from Whole Exome Sequencing Analysis of the Patients with Biliary Tract Cancer.
Yoon KA; Woo SM; Kim YH; Kong SY; Han SS; Park SJ; Lee WJ
Genomics Inform; 2018 Dec; 16(4):e35. PubMed ID: 30602096
[TBL] [Abstract][Full Text] [Related]
25. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
26. Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers.
Papadopoulou K; Murray S; Manousou K; Tikas I; Dervenis C; Sgouros J; Rontogianni D; Lakis S; Bobos M; Poulios C; Pervana S; Lazaridis G; Fountzilas G; Kotoula V
Am J Cancer Res; 2018; 8(1):2-15. PubMed ID: 29416916
[TBL] [Abstract][Full Text] [Related]
27. Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
Dong LQ; Shi Y; Ma LJ; Yang LX; Wang XY; Zhang S; Wang ZC; Duan M; Zhang Z; Liu LZ; Zheng BH; Ding ZB; Ke AW; Gao DM; Yuan K; Zhou J; Fan J; Xi R; Gao Q
J Hepatol; 2018 Jul; 69(1):89-98. PubMed ID: 29551704
[TBL] [Abstract][Full Text] [Related]
28. Molecular and immunohistochemical analysis of intraductal papillary neoplasms of the biliary tract.
Abraham SC; Lee JH; Hruban RH; Argani P; Furth EE; Wu TT
Hum Pathol; 2003 Sep; 34(9):902-10. PubMed ID: 14562286
[TBL] [Abstract][Full Text] [Related]
29. Multigene mutational profiling of biliary tract cancer is related to the pattern of recurrence in surgically resected patients.
Conci S; Ruzzenente A; Simbolo M; Bagante F; Rusev B; Isa G; Lawlor RT; Pedrazzani C; Iacono C; Guglielmi A; Scarpa A
Updates Surg; 2020 Mar; 72(1):119-128. PubMed ID: 32020551
[TBL] [Abstract][Full Text] [Related]
30. Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer.
Cajuso T; Hänninen UA; Kondelin J; Gylfe AE; Tanskanen T; Katainen R; Pitkänen E; Ristolainen H; Kaasinen E; Taipale M; Taipale J; Böhm J; Renkonen-Sinisalo L; Mecklin JP; Järvinen H; Tuupanen S; Kilpivaara O; Vahteristo P
Int J Cancer; 2014 Aug; 135(3):611-23. PubMed ID: 24382590
[TBL] [Abstract][Full Text] [Related]
31. Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA.
Astier C; Ngo C; Colmet-Daage L; Marty V; Bawa O; Nicotra C; Ngo-Camus M; Italiano A; Massard C; Scoazec JY; Smolenschi C; Ducreux M; Hollebecque A; Postel-Vinay S
Exp Hematol Oncol; 2024 Jan; 13(1):2. PubMed ID: 38191492
[TBL] [Abstract][Full Text] [Related]
32. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
Chow OS; Kuk D; Keskin M; Smith JJ; Camacho N; Pelossof R; Chen CT; Chen Z; Avila K; Weiser MR; Berger MF; Patil S; Bergsland E; Garcia-Aguilar J
Ann Surg Oncol; 2016 Aug; 23(8):2548-55. PubMed ID: 27020587
[TBL] [Abstract][Full Text] [Related]
33. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity.
Fujimoto A; Furuta M; Shiraishi Y; Gotoh K; Kawakami Y; Arihiro K; Nakamura T; Ueno M; Ariizumi S; Nguyen HH; Shigemizu D; Abe T; Boroevich KA; Nakano K; Sasaki A; Kitada R; Maejima K; Yamamoto Y; Tanaka H; Shibuya T; Shibata T; Ojima H; Shimada K; Hayami S; Shigekawa Y; Aikata H; Ohdan H; Marubashi S; Yamada T; Kubo M; Hirano S; Ishikawa O; Yamamoto M; Yamaue H; Chayama K; Miyano S; Tsunoda T; Nakagawa H
Nat Commun; 2015 Jan; 6():6120. PubMed ID: 25636086
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of K-ras and TP53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer.
Bleeker WA; Hayes VM; Karrenbeld A; Hofstra RM; Verlind E; Hermans J; Poppema S; Buys CH; Plukker JT
Dis Colon Rectum; 2001 Mar; 44(3):358-63. PubMed ID: 11289281
[TBL] [Abstract][Full Text] [Related]
35. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
[TBL] [Abstract][Full Text] [Related]
36. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer.
Wang K; Kan J; Yuen ST; Shi ST; Chu KM; Law S; Chan TL; Kan Z; Chan AS; Tsui WY; Lee SP; Ho SL; Chan AK; Cheng GH; Roberts PC; Rejto PA; Gibson NW; Pocalyko DJ; Mao M; Xu J; Leung SY
Nat Genet; 2011 Oct; 43(12):1219-23. PubMed ID: 22037554
[TBL] [Abstract][Full Text] [Related]
37. Development of a rapid and practical mutation screening assay for human lung adenocarcinoma.
Choi H; Kratz J; Pham P; Lee S; Ray R; Kwon YW; Mao JH; Kang HC; Jablons D; Kim IJ
Int J Oncol; 2012 Jun; 40(6):1900-6. PubMed ID: 22407457
[TBL] [Abstract][Full Text] [Related]
38. Exome sequencing of liver fluke-associated cholangiocarcinoma.
Ong CK; Subimerb C; Pairojkul C; Wongkham S; Cutcutache I; Yu W; McPherson JR; Allen GE; Ng CC; Wong BH; Myint SS; Rajasegaran V; Heng HL; Gan A; Zang ZJ; Wu Y; Wu J; Lee MH; Huang D; Ong P; Chan-on W; Cao Y; Qian CN; Lim KH; Ooi A; Dykema K; Furge K; Kukongviriyapan V; Sripa B; Wongkham C; Yongvanit P; Futreal PA; Bhudhisawasdi V; Rozen S; Tan P; Teh BT
Nat Genet; 2012 May; 44(6):690-3. PubMed ID: 22561520
[TBL] [Abstract][Full Text] [Related]
39. Use of a High-Throughput Genotyping Platform (OncoMap) for
Kim D; Hong YS; Kim JE; Kim KP; Lee JL; Chun SM; Kim J; Jang SJ; Kim TW
Cancer Res Treat; 2017 Jan; 49(1):37-43. PubMed ID: 27121720
[TBL] [Abstract][Full Text] [Related]
40. Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma.
Rimini M; Macarulla T; Burgio V; Lonardi S; Niger M; Scartozzi M; Rapposelli IG; Aprile G; Ratti F; Pedica F; Verdaguer H; Nappo F; Nichetti F; Lai E; Valgiusti M; Cappetta A; Febregat C; Fassan M; De Braud F; Puzzoni M; Frassineti GL; Simionato F; De Cobelli F; Aldrighetti L; Fornaro L; Cascinu S; Casadei-Gardini A
Eur J Cancer; 2022 Aug; 171():232-241. PubMed ID: 35749808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]